Ruzilya Usmanova

7 ta ish

Tashkent Pediatric Medical Institute

1. Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?

   Ruzilya Usmanova, Nargiza Parpieva, Hayk Davtyan +6

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20211 iqtibos

   ABIABI:AkademIndex/2026.other.262607

2. Adherence of drug-resistant tuberculosis patients to treatment in Tashkent, 2019-2020

   Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko +3

   MaqolaTuberculosis Research and Epidemiology20210 iqtibos

   ABIABI:AkademIndex/2021.article.002154

3. Treatment of multidrug-resistant tuberculosis in Uzbekistan from 2012 to 2018: does practice follow policy?

   Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko +8

   MaqolaTuberculosis Research and Epidemiology20210 iqtibos

   ABIABI:AkademIndex/2021.article.010203

4. The impact of the COVID-19 pandemic on tuberculosis detection in Tashkent, Uzbekistan

   Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko +6

   MaqolaDiverse Scientific Research Studies20230 iqtibos

   ABIABI:AkademIndex/2023.article.011428

5. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

   Ilaria Motta, Martina Cusinato, Andrew Ludman +15

   MaqolaOAOchiq kirishCardiac electrophysiology and arrhythmiasAntimicrobial Agents and Chemotherapy20240 iqtibos

   ABIABI:AkademIndex/2024.article.000869

6. The effectiveness of pulmonary tuberculosis treatment during the COVID-19 pandemic

   Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko +6

   MaqolaCOVID-19 Prevention and Impact20240 iqtibos

   ABIABI:AkademIndex/2024.article.008693

7. Evaluation of TB treatment outcomes in outpatient settings during the COVID-19 pandemic

   Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko

   MaqolaTuberculosis Research and Epidemiology20250 iqtibos

   ABIABI:AkademIndex/2025.article.010588